Princeton, NJ, May 15, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has achieved a major milestone by completing their preclinical formulation development for iQ-007, a novel anticonvulsant compound.
In the last two months, the new formulation of its lead compound iQ-007 was tested in an extensive pharmacokinetic study after oral administration in male and female rats. The results show excellent bioavailability, clear dose linearity over a large dose range from 5-400 mg/kg, and most importantly, a tripling of the elimination half-life. No gender differences were observed and based on the subsequent population analysis, this new formulation will allow the required threshold concentration to be reached within 24 hours, with a three times daily administration. Assuming a doubling of half-life in humans, which is often seen in antiepileptic drugs, this would result in a twice daily administration in the clinic trial.
“This is very good news and allows us to complete the IND-enabling package and move to the clinic development phase as soon as possible.” said iQure Chief Operating Officer, Henk de Wilde.
About iQure Pharma
iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at email@example.com.